Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study

BACKGROUND: This study in patients with rheumatoid arthritis (RA) treated with infliximab describes prospectively the course of (anti)infliximab levels within an infusioncycle to assess at what moment patients develop low/no infliximab trough levels and/or detectable anti-infliximab levels. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Bemt, Bart JF, den Broeder, Alfons A, Wolbink, GJ, Hekster, Yechiel A, van Riel, Piet LCM, Benraad, Bart, van den Hoogen, Frank HJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034722/
https://www.ncbi.nlm.nih.gov/pubmed/21232150
http://dx.doi.org/10.1186/1471-2474-12-12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034722/
https://www.ncbi.nlm.nih.gov/pubmed/21232150
http://dx.doi.org/10.1186/1471-2474-12-12

Ejemplares similares